Resistance to hormone therapy in breast cancer cells promotes autophagy and EGFR signaling pathway
Konstantinos E. Siatis, Efstathia Giannopoulou, Dimitra Manou, Panagiotis Sarantis, Michalis V. Karamouzis, Sofia Raftopoulou, Konstantinos Fasseas, Fatimah Mohammed A. Alzahrani, Haralabos P. Kalofonos, Achilleas D. Theocharis
Abstract
The development of resistance to hormone therapy caused by both fulvestrant and tamoxifen promotes autophagy with concomitant apoptosis evasion, rendering cells capable of surviving and growing. The fact that resistance also triggers ERBB family signaling pathways, which are poorly inhibited by tyrosine kinase inhibitors might attribute to cells' aggressiveness. It is obvious that the development of endocrine therapy resistance involves a complex interplay between deregulated ERBB signaling and autophagy that may be considered in clinical practice.